Comparative Pharmacology
Head-to-head clinical analysis: SAPHRIS versus SEZABY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SAPHRIS versus SEZABY.
SAPHRIS vs SEZABY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asenapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors; dopamine D2, D3, and D4 receptors; and alpha2-adrenergic receptors. It also has moderate affinity for histamine H1 and alpha1-adrenergic receptors, and low affinity for muscarinic M1 receptors.
Positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
5 mg sublingually twice daily, may increase to 10 mg twice daily based on tolerability and efficacy.
58 mg subcutaneously once monthly (every 30 days).
None Documented
None Documented
Terminal elimination half-life is 30-40 hours, supporting once-daily dosing.
The terminal elimination half-life of Sezaby is approximately 24 hours in healthy adults. This supports once-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
After oral administration, approximately 50% of the dose is excreted in urine (mostly as metabolites, <1% unchanged) and 40% in feces (mostly as metabolites).
Sezaby undergoes extensive hepatic metabolism, with approximately 75% of the dose excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites. Renal clearance accounts for less than 5% of total clearance.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic